GMAB
$26.36
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Recent News
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches
Genmab A/S (NASDAQ:GMAB) executives highlighted a “very strong year” in 2025 and outlined a catalyst-heavy 2026 that could set up multiple launches in 2027, according to remarks made by Chief Financial Officer Anthony Pagano and Chief Commercial Officer Brad Bailey at a Leerink Partners event hosted
Genmab A/S Teases 2026 Wave of Registrational Readouts for EPKINLY, Rina-S and Petosemtamab
Genmab A/S (NASDAQ:GMAB) executives outlined a slate of late-stage clinical catalysts expected in 2026, highlighting multiple potentially registrational readouts across three key programs: EPKINLY, Rina-S and petosemtamab. Speaking at a Barclays fireside chat hosted by analyst James Gordon, Chief Fi
How The Genmab (CPSE:GMAB) Narrative Is Shifting As 2026 Catalyst Risks Build
Genmab’s analyst fair value estimate has been adjusted from DKK 2,182.25 to DKK 2,237.63, while some bullish price targets now cluster in the DKK 2,400 to DKK 2,500 range and around US$40 to US$41.50. These shifts reflect fresh reactions to earnings, product updates, acquisitions and the debate over how 2026’s heavy catalyst calendar could affect longer term earnings power. Read on to see how you can track this evolving narrative and what to watch as analyst views continue to adjust. Analyst...
Netflix upgraded, Pinterest downgraded: Wall Street's top analyst calls
Netflix upgraded, Pinterest downgraded: Wall Street's top analyst calls
Here Are Monday’s Top Wall Street Analyst Research Calls: AppLovin, Blue Owl Capital, CrowdStrike, Dutch Bros., Jet Blue, Novo Nordisk, PayPal, Twilio, and More
Pre-Market Stock Futures: The futures are trading lower after a dreadful Friday and week, one that could be laying the foundation for a larger and more intense sell-off. The combination of the sell-off in Nvidia Corp. (NASDAQ: NVDA), the much higher producer price index print, the ongoing confusion over the tariffs, and the weekend military ... Here Are Monday’s Top Wall Street Analyst Research Calls: AppLovin, Blue Owl Capital, CrowdStrike, Dutch Bros., Jet Blue, Novo Nordisk, PayPal, Twilio, a